RespireRx Pharmaceuticals (OTCQB:RSPI) Inc Research Fellow Jeff Witkin joined Proactive to discuss the publication of a paper detailing the company's newest candidate D5-KRM-II-81, which is a so-called GABAkine - a type of medicine which enhances the inhibitory neurotransmitter in the brain. This latest asset is a structurally related analog to KRM-II-81, which, as previously reported, RespireRX's EndeavourRx business unit is advancing for the treatment of epilepsy and chronic pain.
RespireRx Pharmaceuticals notes publication of paper on newest GABAkine analog
